{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:32:27Z","timestamp":1760239947461,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.hoc.2023.06.012","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:55:13Z","timestamp":1691801713000},"page":"e1-e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Mark","family":"Bustoros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Gribbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.hoc.2023.06.012_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.23880","article-title":"Extramedullary Waldenstrom macroglobulinemia","volume":"90","author":"Banwait","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.hoc.2023.06.012_bib3","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2023.06.012_bib4","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2023.06.012_bib5","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2015-04-537498","article-title":"Familial predisposition and genetic risk factors for lymphoma","volume":"126","author":"Cerhan","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.06.012_bib6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2023.06.012_bib7","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.06.012_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjh.15201","article-title":"Prevalence and survival of smouldering Waldenstrom macroglobulinaemia in the United States","volume":"184","author":"Pophali","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2023.06.012_bib9","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol. Nov"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol. Apr"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol. Apr"},{"issue":"3","key":"10.1016\/j.hoc.2023.06.012_bib12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2023.06.012_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.06.012_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.26082","article-title":"Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management","volume":"96","author":"Gertz","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bjh.13091","article-title":"Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies","volume":"168","author":"Varettoni","year":"2015","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2023.06.012_bib17","first-page":"S91","article-title":"Prevalence, clinical aspects, and natural history of IgM MGUS","volume":"78","author":"McMaster","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/sonc.2003.50051","article-title":"Asymptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"Alexanian","year":"2003","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.06.012_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CLML.2011.n.012","article-title":"Factors predicting transformation of asymptomatic IgM monoclonal gammopathy","volume":"11","author":"Greco","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.hoc.2023.06.012_bib20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/sj.leu.2403442","article-title":"Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders","volume":"18","author":"Morra","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/sonc.2003.50056","article-title":"Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease","volume":"30","author":"Cesana","year":"2003","journal-title":"Semin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2023.06.012_bib22","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2005.06.147","article-title":"Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system","volume":"23","author":"Baldini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.06.012_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/10428194.2019.1689393","article-title":"Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenstrom macroglobulinemia","volume":"61","author":"Merli","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2023.06.012_bib24","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2018.190181","article-title":"MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2023.06.012_bib25","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.06.012_bib26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2023.06.012_bib27","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.06.012_bib28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol. Apr 10"},{"issue":"8","key":"10.1016\/j.hoc.2023.06.012_bib29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2014.65","article-title":"Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"28","author":"Xu","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2023.06.012_bib30","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2023.06.012_bib31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.18502","article-title":"Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia","volume":"200","author":"Moreno","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.06.012_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstrom's Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.hoc.2023.06.012_bib34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.06.012_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.06.012_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","article-title":"Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemia","volume":"128","author":"Hunter","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2023.06.012_bib37","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:20:19Z","timestamp":1760185219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889858823001028"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.06.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr\u00f6m Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}